baber/WOPTO huggingface dataset:
Patent NZ-525231-A (NZ)
Title: Phospholipid stabilised feno-fibrate microparticles for pharmaceutical use
Inventor: GUIVARC H POL-HENRI
IPC: A61K31/505
Filed: 2001-04-20
Abstract: An orally administered pharmaceutical composition comprising microparticles of solid fenofibrate that are stabilized by a phospholipid surface active substance that is present during the preparation of the microparticles, wherein a therapeutically effective amount of the composition provides a quantity of fenofibrate active species to a fasted human patient in need of treatment by fenofibrate that is greater than 80 % of the quantity of fenofibrate active species provided by the same amount of the composition when administered to the same patient who has been fed a high fat meal consisting of at least 1000 calories, 50 % of which are from fat is disclosed. Furthermore a method of treatment of dislipidemia and dislipoproteinemia in a mammal consisting of administering a therapeutically effective oral dosage form comprising microparticles of a solid fibrate that are stabilized by a phospholipid surface active substance wherein the dosage form provides into the blood of the patient in a fasted state a therapeutically effective amount of a fibrate active species that is at least 90 % of the AUC (area under the curve) amount of the fibrate active species provided by the same dosage form into the blood of the same patient when the patient is in a fed state is disclosed. Also disclosed is a composition comprising phospholipid stabilised feno-fibrate microparticles is disclosed, wherein: the microparticles of fenofibrate are prepared by a process comprising the steps of (a) mixing at high shear an admixture of fenofibrate and a phospholipid substance in an aqueous carrier in the absence of an organic solvent within a first temperature range at or above the melting point of fenofibrate to form a heated suspension wherein fenofibrate is molten; (b) homogenizing said heated suspension in a first pressure range and within said first temperature range to form a heated homogenate containing fenofibrate; (c) cooling said heated homogenate to a second temperature range below the melting temperature of fenofibrate to form a transiently stable cooled homogenate containing fenofibrate; (d) applying a particle stabilizing energetic process to said cooled homogenate within a second temperature range below the melting temperature of fenofibrate and in a second pressure range to form a cooled dispersion of small particles containing fenofibrate, and (e) drying said cooled dispersion to form dried small particles containing fenofibrate.
Patent NZ-525656-A (NZ)
Title: Indolylmaleimide derivatives as protein kinase C inhibitors
Inventor: ALBERT RAINER
IPC: A61P17/06
Filed: 2001-11-05
Abstract: Indolylmaleimide derivatives of formula (I) comprising either a substituted phenyl, naphthyl, tetrahydronaphthyl, quinazolinyl, quinolyl, isoquinolyl or a pyrimidinyl residue are disclosed, wherein these indolylmaleimide derivatives are suitable for the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer.
Patent NZ-528069-A (NZ)
Title: Organic matter disposal method using material circulation system and organic matter disposal system
Inventor: TODA TATSUKI
IPC: B09B3/00
Filed: 2002-02-15
Abstract: A disposal method and disposal system for sharply reducing the residue and enhancing the sustainability and stability of disposal in disposal of organic waste are provided. The matter inside the solid phase decomposer is transported to a liquid phase decomposer I and is decomposed by land microorganisms at a solid phase decomposer III. The highly viscous products built up at that time are transported to the liquid phase decomposer I where they are dissolved in water and converted to sludge by aqueous microorganisms. The newly introduced organic waste is washed at the liquid phase decomposer I, transported together with the produced sludge to the solid phase decomposer III, and again decomposed by land microorganisms. For the transport of the matter inside the solid phase decomposer to the liquid phase decomposer I and the transport of the organic waste to the solid phase decomposer III, a solid/liquid circulator II having a twin screw structure is used. Further, at a demoisturizer IV, the moisture is separated from the gas produced at the solid phase decomposer III and the moisture is returned to the liquid phase decomposer. Further, the minimum necessary limit of gas is sent to a deodorizer V where it is deodorized and discharged as ordinary air.
Patent NZ-535189-A (NZ)
Title: Work platform for roof construction work
Inventor: CUNNIFFE NIGEL JAMES
IPC: E04G3/26
Filed: 2003-03-20
Abstract: A work platform for roof construction work includes an upper surface for working on the roof and a lower surface for storage of work material, the step between the work surfaces comprising an elongate material transfer section, and the upper work surface including a covered roof access section. The invention also provides a method of roof construction work utilising the work platform. (61) Addition to 535189
Patent NZ-538692-A (NZ)
Title: Chemical process involving selective reduction of a nitro moiety
Inventor: CHENG YUN-XING
Filed: 2002-04-18
Abstract: Disclosed is a method for selectively reducing a nitro moiety ortho to an amino substituent on a phenyl or pyridyl ring of a compound in the presence of a nitro moiety para to an amino substituent on the phenyl or pyridyl ring of the compound, comprising treating a solution of the compound in a solvent with a palladium catalyst in the presence of hydrogen.
Patent NZ-538964-A (NZ)
Title: Method of preparing dry powder inhalation compositions
Inventor: ZENG XIAN-MING
IPC: A61K9/72
Filed: 2003-08-21
Abstract: The invention provides a method of preparing a dry powder inhalation composition comprising a pharmaceutically acceptable particulate carrier, a first particulate inhalant medicament and a second particulate inhalant medicament. Also provided are dry powder compositions and methods of using them with a dry powder inhalation device.
Patent NZ-542459-A (NZ)
Title: Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders
Inventor: MAUVERNAY ROLLAND-YVES
IPC: A61K9/20
Filed: 2004-03-15
Abstract: The disclosure relates to a subcutaneous delivery system comprising a biodegradable polymeric matrix and at least one of the pharmacologically active substances of general formula (I): wherein A represents an amino group -NH2 or an ammonium group -NH3+ or a residue as defined in the specification. It relates also to a process for its preparation and to its use for the preparation of a medicament.
Patent NZ-544264-A (NZ)
Title: Oriented strand boards with various resin compositions of melamine formaldehyde and optionally urea and aromatic hydroxyl compounds
Inventor: VERMEULEN JACOBUS ADRIAAN ANTO
IPC: B32B21/02
Filed: 2004-06-28
Abstract: Oriented strand board (OSB), comprising a core layer and two face layers, whereby the face layers comprise an adhesive composition, wherein the adhesive composition in at least one of the face layers comprises a resin composition comprising melamine, formaldehyde, optionally urea and aromatic hydroxyl compounds, wherein the molar ratio of melamine to formaldehyde is 1:0.8-4.0, the molar ratio of melamine to urea is 1:0-2.0 and the molar ratio of melamine to aromatic hydroxyl compounds is 1:0-2.0. In a preferred embodiment, both the face layers and the core layer comprise the said adhesive composition. The OSB's according to the invention can meet the OSB/3 and even the OSB/4 requirements in the EN 300 standards.
Patent NZ-544735-A (NZ)
Title: A method for producing a signature on a DVD in the lead-in zone
Inventor: SOLLISH BARUCH
Filed: 2001-11-27
Abstract: A method for producing a signature on a digital optical disk (DVD) is disclosed. The method includes altering at least one component in the lead-in-zone of the DVD. Various embodiments include changing the burst Cutting Area (BCA) descriptor value to 0x80, and changing the disc manufacturing information (DMI).
Patent NZ-547171-A (NZ)
Title: Ortho-substituted pentafluoride sulfanyl-benzenes, method for the production thereof and the use thereof in the form of valuable synthesis intermediate stages
Inventor: KLEEMANN HEINZ-WERNER
IPC: C07C381/00
Filed: 2004-11-03
Abstract: The disclosure relates to pentafluoride-sulfanyl-benzenes of formula (I), wherein groups from R1 to R5 correspond to meanings given in specification. These pentafluoride-sulfanyl-benzenes are useful as intermediates, for example for producing drugs, diagnosis agents, liquid crystals, polymers, herbicides, fungicidals, nematicidals, parasiticides, insecticides, acaricides and arthropodicides.
Patent NZ-548856-A (NZ)
Title: Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
Inventor: SINGH NIKHILESH N
IPC: A61K9/00
Filed: 2005-02-16
Abstract: Disclosed is the use of (a) zolpidem or a pharmaceutically acceptable salt thereof; (b) a carbonate buffer; and (c) a bicarbonate buffer in the manufacture of a medicament for the treatment of insomnia in a patient in need thereof, wherein the medicament is formulated to provide between about 1mg to about 5mg of (a) and wherein (b) and (c) are present in the medicament in a weight ratio of about 1:1 to about 1:10 and wherein the medicament is formulated for delivery of (a) across the oral mucosa of the patient. Also disclosed is a pharmaceutical composition comprising about 1mg to about 5 mg of zolpidem or a pharmaceutically acceptable salt; a carbonate buffer; and a bicarbonate buffer, wherein the carbonate buffer and bicarbonate buffer are present in a carbonate: bicarbonate weight ratio of about 1:1 to about 1:10.
Patent NZ-551366-A (NZ)
Title: Keratin-binding polypeptides
Inventor: BARG HEIKO
IPC: A61K8/64
Filed: 2005-05-24
Abstract: Disclosed is are keratin-binding protein active substances, and also to the production and use thereof. Particularly suitable keratin-binding polypeptides are sequences which are contained in human desmoplakin or are derived therefrom by altering the human desmoplakin polypeptide sequences such as amino acid insertions, substitutions or deletions. The polypeptide sequences of the human desmoplakin is represented in SEQ ID NO: 1. A suitable keratin-binding domain (domain B) is the polypeptide sequence SEQ ID NO: 1, position 2193 2481, in addition to functional equivalents thereof. An additional keratin-binding domain (domain C) is the polypeptide sequence SEQ ID NO: 1, position 2606 2871 and the functional equivalents thereof.
Patent NZ-552033-A (NZ)
Title: Sub-ambient refrigerating cycle where the pressure of vaporized refrigerant is increased prior to heat removal
Inventor: WYATT WILLIAM GERALD
IPC: F25B1/00
Filed: 2005-06-10
Abstract: A cooling system (10) for an apparatus that generates a substantial amount of heat is disclosed. The object of an invention is to introduce an enhanced cooling system (10) that takes into consideration the undesirable problem of greater size, weight and power consumption. The system (10) includes a method in which a fluid refrigerant is first brought into thermal communication with the heat generating structure (12). The heat from the heat generating structure (12) causes the liquid refrigerant to boil and vaporize so that the refrigerant can absorb the heat from the heat generating structure (12). The pressure of the refrigerant is maintained so that the refrigerant has a boiling temperature less than the temperature of the heat-generating structure (12). The system (10) is also provided with a heat exchanger (16) so that the heat from the vaporized refrigerant is removed and the vaporized refrigerant is condensed to liquid. The system (10) is characterised by a compressor (14) with a relatively small power input that increases the pressure of the vaporized refrigerant before the heat from the vaporized refrigerant is removed.
Patent NZ-552397-A (NZ)
Title: Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
Inventor: MOLINO BRUCE F
IPC: A61K31/4709
Filed: 2005-07-15
Abstract: Disclosed are substituted tetrahydroisoquinolines as represented by general formula (I), wherein X is a fused bicyclic carbocycle or heterocycle selected from the group consisting of benzofuranyl, benzo[b]thiophenyl, benzoisothiazolyl, benzoisoxazolyl, indazolyl, indolyl, isoindolyl, indolizinyl, benzoimidazolyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3a]pyridinyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, indenyl, indanyl, dihydrobenzocycloheptenyl, tetrahydrobenzocycloheptenyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, indolinyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, 4H-quinolizinyl, 9aH-quinolizinyl, quinazolinyl, cinnolinyl, phthalazinyl, quinoxalinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 2H-chromenyl, 4H-chromenyl, and a fused bicyclic carbocycle or a fused bicyclic heterocycle optionally substituted with 1-4 substituents, and where the remaining substituents are as defined herein. It is further disclosed that the compounds are useful for the treatment of conditions such as attention deficit disorder hyperactivity disorder (ADHD), cognition impairment, anxiety disorder, panic disorder, obsessive compulsive disorder (OCD), posttraumatic stress disorder (PTSD), acute stress disorder, social phobia, simple phobia, pre-menstrual dysphoric disorder (PMDD), social anxiety disorder (SAD), major depressive disorder (MDD), bipolar or manic-depressive disorder, eating disorder, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, analgesia, substance abuse disorder, Lesch-Nyhan syndrome, neurodegenerative diseases, psychiatric symptoms, movement disorder, tardive dyskinesia, supranuclear palsy, sleep related eating disorder (SRED), night eating syndrome (NES), urinary incontinence, migraine, lower back pain, neuropathic pain, fibromyalgia syndrome (FS), chronic fatigue syndrome (CFS), sexual dysfunction, and thermoregulatory disorder. ;
Patent NZ-552743-A (NZ)
Title: Plugging device and method
Inventor: BORLAND NEAL CHRISTOPHER
IPC: F16L55/134
Filed: 2005-07-27
Abstract: A plugging device for impeding the flow of a first fluid in a pipe is provided. The device includes an expandable bladder to receive a second fluid; and, a flexible adaptor providing a fluid communication pathway for the second fluid between the bladder and a pump. At least part of the flexible adaptor is made from a substantially heat resistant material.
Patent NZ-553288-A (NZ)
Title: 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
Inventor: RIEGER JAYSON M
IPC: A61K31/7076
Filed: 2005-08-02
Abstract: Disclosed is a compound having formula (I) wherein the substituents are disclosed within the specification; or a pharmaceutically acceptable salt thereof. Also disclosed is the use of a compound of formula (I) for the preparation of a medicament fore preventing or treating a pathological condition or symptom in a mammal wherein the activity of A3 adenosine receptors is implicated and agonism of such activity is desired such as an inflammatory response.
Patent NZ-554830-A (NZ)
Title: Bismuth flouride based nanocomposites as electrode materials
Inventor: AMATUCCI GLENN G
IPC: H01M4/02
Filed: 2005-09-30
Abstract: The disclosure relates to primary and secondary electrochemical energy storage systems, particularly to such systems as battery cells, which use materials that take up and release ions as a means of storing and supplying electrical energy. The disclosure particularly relates an electrochemical cell comprising: a negative electrode; a positive electrode comprising a bismuth fluoride compound nanocomposite, wherein the bismuth fluoride component of the nanoparticle comprises Bi3+; a separator disposed between the negative and positive electrodes. Particularly disclosed is a positive electrode composition comprising a nanocrystalline bismuth fluoride compound, wherein the bismuth fluoride compound comprises Bi3+, and wherein the maximum energy density of the composition is 7170 Wh/l-1.
Patent NZ-575702-A (NZ)
Title: Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
Inventor: CLOZEL MARTINE
IPC: A61K45/06
Filed: 2007-08-28
Abstract: Disclosed is a product containing the compound of formula (I) wherein the substituents are defined in the specification, or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having a PDE5 IC50 equal or lower than 1 ìM, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a diseases selected from hypertension, pulmonary hypertension, diabetic arteriopathy, heart failure, erectile dysfunction and angina pectoris.
Patent NZ-580133-A (NZ)
Title: Mutagenized tobacco plant as seed culture for the production of oil for energetic, industrial and alimentary uses
Inventor: FOGHER CORRADO
IPC: A23L33/00
Filed: 2007-08-27
Abstract: Disclosed is a mutagenised tobacco plant characterised in that it produces a seed quantity of at least 4000 kilograms per hectare at a seeding density of about 125,000 plants per hectare. Also disclosed is the use of the plant, for the production of biomass for biochemical conversion or for thermochemical conversion by direct combustion, carbonisation, pyrolysis, gasification, anaerobic digestion, aerobic digestion, alcoholic fermentation or steam explosion procedures.
Patent NZ-586964-A (NZ)
Title: Derivatives of indole 2-carboxamides and azaindole 2-carboxamides substituted by a silanyle group, preparation thereof and therapeutic use thereof
Inventor: DUBOIS LAURENT
IPC: A61K31/4439
Filed: 2009-01-20
Abstract: The disclosure relates to substituted indole-2-carboxamide and azaindole-2-carboxamide derivatives of structural formula (I) in the form of a base or of an addition salt with an acid, and also in the form of a hydrate or of a solvate, wherein the variables are as defined in the specification. Also disclosed is a process for the preparation of these compounds of formula (I) and their therapeutic use for preventing or treating pathologies in which receptors of TRPV1 type are involved. These compounds are suitable for preventing or treating pain, inflammation, metabolic disorders, urological disorders, gynaecological disorders, gastrointestinal disorders, respiratory disorders, psoriasis, pruritus, dermal, ocular or mucous irritations, herpes, zona, multiple sclerosis, depression and cancers.
Patent NZ-592747-A (NZ)
Title: Catheterisation device including drainage channel and lubricable guidewire channel
Inventor: ANDRICH DANIELA
IPC: A61M25/00
Filed: 2009-10-28
Abstract: A device for urinary catheterisation. The device includes: a catheter (10) having an elongate body (12) provided with a distal tip (16), a proximal end (18), and a drainage channel (14) and a separate guidewire channel (32) extending therethrough. A guidewire (38) extends through the guidewire channel for guiding the catheter upon insertion. A lubrication port is located at or towards the proximal end of the elongate body, the lubrication port comprising a side arm (34) in fluid communication with the guidewire channel for the introduction of a guidewire lubrication fluid into the guidewire channel.
Patent NZ-594740-A (NZ)
Title: Solid pharmaceutical composition comprising amlodipine and losartan with improved stability
Inventor: KIM KYEONG SOO
IPC: A61K9/16
Filed: 2009-06-05
Abstract: 594740 Disclosed herein is a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising granular forms of amlodipine and losartan which are separated from each other, and a stabilizing agent, wherein the stabilizing agent is an anti-oxidant selected from the group consisting of butylated hydroxytoluene, butylated hydroxyanisole, tocopherol, ascorbic acid, erythorbic acid, citric acid, ascorbyl palmitic acid, ethylene diamine tetracetic acid, sodium pyrosulfite, and a mixture thereof, and is used in an amount ranging from 0.005 to 5% by weight based on the total weight of the composition.
Patent NZ-598291-A (NZ)
Title: Quinoline derivative-containing pharmaceutical composition
Inventor: BANDO MASASHI
IPC: A61P35/00
Filed: 2010-08-16
Abstract: 598291 Disclosed herein is a pharmaceutical composition comprising: a compound represented by formula (I),and an alkali earth metal caronate. The pharmaceutical composition has excellent dissolvability, is stable even after long-term storage, and is useful as a prophylactic/therapeutic agent for tumors. (In the formula, R1 represents a hydrogen atom, a C1-6 alkyl group or a C3-8 cycloalkyl group; and R2 represents a hydrogen atom or a methoxy group.) Specifically wherein the compound represent by the formula (I) is 4-(3-chloro-4- (cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate.
Patent NZ-598407-A (NZ)
Title: Tissue restoration devices, systems, and methods
Inventor: NAVIA JOSE A
IPC: A61B17/12
Filed: 2010-08-24
Abstract: 598407 Tissue restoration devices, systems, and methods are disclosed. In at least one embodiment, an implantable restraining device of the present disclosure comprises a first engaging component and a second engaging component, the first and second engaging components configured for laparoscopic insertion into a body cavity, and at least one connector coupled to the first engaging component and the second engaging component, the at least one connector capable of comprising a first configuration relative to the first engaging component and the second engaging component where the first engaging component and the second engaging component are positioned relative to one another to fit within a laparoscopic port, the at least one connector capable of comprising a second configuration relative to the first engaging component and the second engaging component whereby the first engaging component and the second engaging component are spaced apart from one another so that an interior space having a value is defined therebetween.
Patent NZ-599468-A (NZ)
Title: Load sense hydraulic pump alignment
Inventor: RASZGA CALIN
IPC: A01G23/08
Filed: 2009-10-12
Abstract: A tree harvester including a chassis, at least one ground engaging mechanism configured to propel the chassis over the ground, a harvesting head including a saw configured to cut trees, a plurality of hydraulic units including a hydraulic motor to power the saw, and a hydraulic control system including a first hydraulic pump providing pressurized hydraulic fluid, a plurality of valves controlling the supply of hydraulic fluids from the first hydraulic pump to the plurality of hydraulic units, a load sense system that detects the load pressure requirements of the plurality of hydraulic units and provides instruction to the first hydraulic pump to produce pressure sufficient to satisfy the requirements of a highest of the load pressure requirements of the plurality of hydraulic units, and a second hydraulic pump providing hydraulic fluid to the harvesting head. The hydraulic motor provides a load sense signal to the load sense system to control operation of the first hydraulic pump and a load sense signal to the second hydraulic pump to control operation of the second hydraulic pump.